Especially since the field of IDH-mutant glioma has been rapidly advancing in recent years, we hope that our review will equip clinicians, scientists, and patients with comprehensive, up-to-date knowledge of the past, present, and future of IDH-mutant targeted strategies for this unique tumor type. Here, IDH2 is linked to central nervous system cancer.